114 related articles for article (PubMed ID: 3870878)
1. Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC.
Cameron LM; LaFrance RJ; Hemens CM; Vaughan K; Rajaraman R; Chubb DC; Goddard PM
Anticancer Drug Des; 1985 Oct; 1(1):27-36. PubMed ID: 3870878
[TBL] [Abstract][Full Text] [Related]
2. Triazene metabolism. V. Chemical and biological properties of N,N-bis-[(1-aryl-3-methyltriazen-3-yl)-methyl]-methylamines: potential prodrugs for the cytotoxic monomethyltriazenes.
Manning HW; Cameron LM; LaFrance RJ; Vaughan K; Rajaraman R
Anticancer Drug Des; 1985 Oct; 1(1):37-43. PubMed ID: 3870879
[TBL] [Abstract][Full Text] [Related]
3. Triazene metabolism. VI. 3-Azidomethyl-3-alkyl-1-aryltriazenes, a new class of anti-tumour triazene with potential pro-drug applications.
Vaughan K; Nicholas G; Singer RD; Roy M; Gibson NW
Anticancer Drug Des; 1987 Dec; 2(3):279-87. PubMed ID: 3449091
[TBL] [Abstract][Full Text] [Related]
4. Triazene metabolism. III. In vitro cytotoxicity towards M21 cells and in vivo antitumour activity of the proposed metabolites of the antitumour 1-aryl-3,3-dimethyltriazenes.
Kohlsmith DJ; Vaughan K; Luner SJ
Can J Physiol Pharmacol; 1984 Apr; 62(4):396-402. PubMed ID: 6733585
[TBL] [Abstract][Full Text] [Related]
5. Antimetastatic action of some triazene derivatives against the Lewis lung carcinoma in mice.
Giraldi T; Houghton PJ; Taylor DM; Nisi C
Cancer Treat Rep; 1978 May; 62(5):721-5. PubMed ID: 657157
[TBL] [Abstract][Full Text] [Related]
6. Kinetic investigation of the aqueous stability and antitumor activity of a hydrosoluble diaryltriazene, AVIS, related to the antimetastatic agent DM-COOK.
Lassiani L; Ebert C; Nisi C; Varnavas A; Zorzet S; Sava G; Boccù E
Pharmazie; 1990 Oct; 45(10):743-5. PubMed ID: 2089382
[TBL] [Abstract][Full Text] [Related]
7. Towards an efficient prodrug of the alkylating metabolite monomethyltriazene: synthesis and stability of N-acylamino acid derivatives of triazenes.
Perry Mde J; Carvalho E; Rosa E; Iley J
Eur J Med Chem; 2009 Mar; 44(3):1049-56. PubMed ID: 18687506
[TBL] [Abstract][Full Text] [Related]
8. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumor activity of methyltriazene prodrugs simultaneously releasing DNA-methylating agents and the antiresistance drug O(6)-benzylguanine.
Wanner MJ; Koch M; Koomen GJ
J Med Chem; 2004 Dec; 47(27):6875-83. PubMed ID: 15615536
[TBL] [Abstract][Full Text] [Related]
10. Biological characterization of a novel antitumor quinolone.
Clement JJ; Burres N; Jarvis K; Chu DT; Swiniarski J; Alder J
Cancer Res; 1995 Feb; 55(4):830-5. PubMed ID: 7850797
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Stevens MF; Hickman JA; Langdon SP; Chubb D; Vickers L; Stone R; Baig G; Goddard C; Gibson NW; Slack JA
Cancer Res; 1987 Nov; 47(22):5846-52. PubMed ID: 3664486
[TBL] [Abstract][Full Text] [Related]
12. Functional-group modifications of dextran for linkage to a diazonium group. A potential vehicle for tumour targeting of antineoplastic triazenes.
Baki AV; Vaughan K
Carbohydr Res; 1982 Jul; 105(1):57-68. PubMed ID: 6180830
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antitumor activity of hydrosoluble analogs of p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt.
Varnavas A; Nisi C; Lassiani L; Sava G; Perissin L; Boccù E
Arzneimittelforschung; 1991 Nov; 41(11):1168-72. PubMed ID: 1810263
[TBL] [Abstract][Full Text] [Related]
14. Triazene drug metabolites. Part 17: Synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes.
Carvalho E; Francisco AP; Iley J; Rosa E
Bioorg Med Chem; 2000 Jul; 8(7):1719-25. PubMed ID: 10976519
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and cytotoxic effects of hydroxymethyl-3-pyridyl- and 2-chloro-5-pyridyltriazene derivatives.
Grancharov KC; Koch M; Volm M; Kolar GF
Cancer Lett; 1988 Aug; 41(3):271-9. PubMed ID: 3409206
[TBL] [Abstract][Full Text] [Related]
16. Modulating effect of new potential antimelanomic agents, spin-labeled triazenes and nitrosoureas on the DOPA-oxidase activity of tyrosinase.
Gadjeva V; Zheleva A; Raikova E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):99-108. PubMed ID: 10738906
[TBL] [Abstract][Full Text] [Related]
17. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
van Tellingen O; Nooijen WJ; Schaaf LJ; van der Valk M; van Asperen J; Henrar RE; Beijnen JH
Cancer Res; 1998 Jun; 58(11):2410-6. PubMed ID: 9622082
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiproliferative activity of O-silylated nucleoside triazene N-oxide derivatives.
Tronchet JM; Grivet C; Grand E; Seman M; Dilda P
Carbohydr Lett; 2000; 4(1):5-12. PubMed ID: 11469337
[TBL] [Abstract][Full Text] [Related]
20. Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
Giraldi T; Nisi C; Connors TA; Goddard PM
J Med Chem; 1977 Jun; 20(6):850-3. PubMed ID: 874961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
